What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Enhancers in Transcription: Mechanisms and Functions

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Enhancers in Transcription

Historical Discovery

The concept of the enhancer emerged from studies of gene regulation in the early 1980s, when researchers investigating the SV40 virus observed that a specific DNA segment could dramatically increase transcription from a linked promoter. This region, located approximately 100 base pairs upstream of the viral early promoter, retained its stimulatory activity even when moved to different positions or flipped in orientation. The term "enhancer" was coined to describe this class of regulatory DNA elements that boost transcription irrespective of their position relative to the gene.

Subsequent work in metazoan systems revealed that enhancers are not viral peculiarities but fundamental components of eukaryotic gene regulation. The discovery that the immunoglobulin heavy-chain gene enhancer could activate transcription in B lymphocytes but not in other cell types established the principle of tissue-specific enhancer activity. This finding provided a molecular explanation for how a single genome can generate diverse cell types with distinct gene expression programs.

Basic Definition

An enhancer is a cis-acting DNA regulatory element that increases the rate of transcription from a target promoter. Unlike promoters, which are located immediately adjacent to the transcription start site, enhancers can be positioned thousands or even millions of base pairs away from their target genes. They function by serving as platforms for the assembly of sequence-specific DNA-binding proteins called transcription factors, which recruit coactivator complexes that ultimately stimulate the basal transcription machinery assembled at the promoter.

Enhancers are typically 100–1000 base pairs in length and contain clusters of binding sites for multiple transcription factors. The combinatorial binding of these factors—rather than the presence of any single protein—determines the enhancer's activity in a given cell type. This combinatorial logic allows a relatively limited number of transcription factors to generate enormous regulatory diversity across different tissues and developmental stages.

Mechanism of Enhancer Action

DNA Looping and Chromatin Architecture

The fundamental challenge posed by enhancer function is spatial: how does a regulatory element located thousands of base pairs from its target promoter exert its effect? The answer lies in the three-dimensional organization of the genome within the nucleus. Enhancers and promoters are brought into physical proximity through the formation of chromatin loops, a process mediated by the protein complexes cohesin and CTCF.

CTCF (CCCTC-binding factor) binds to specific DNA sequences and, together with cohesin, participates in the formation of loop structures that organize the genome into topologically associating domains (TADs). These domains are megabase-scale regions of the genome that preferentially interact with themselves rather than with neighboring regions. Enhancers typically act on promoters within the same TAD, and the boundaries of these domains constrain enhancer-promoter communication.

The loop extrusion model proposes that cohesin complexes load onto chromatin and actively extrude DNA loops until they encounter CTCF-bound boundary elements. This process brings distant regulatory elements into proximity, allowing enhancer-promoter contacts to form. The dynamic nature of these loops means that enhancer-promoter interactions are probabilistic rather than fixed: a given enhancer may contact its target promoter only a fraction of the time, yet this transient interaction can be sufficient to drive robust transcriptional activation.

Transcription Factor Binding

Enhancer function begins with the binding of sequence-specific transcription factors to their cognate DNA motifs. These factors recognize 6–12 base pair DNA sequences with varying degrees of specificity. The affinity of a transcription factor for its binding site, the concentration of the factor in the nucleus, and the accessibility of the chromatin at the enhancer all contribute to the probability of binding.

Pioneer transcription factors deserve particular mention. These proteins, such as FOXA1 and OCT4, can bind to their target sequences even within condensed chromatin, where most other factors cannot access their binding sites. By binding first, pioneer factors initiate chromatin remodeling—the ATP-dependent repositioning or eviction of nucleosomes—which then allows additional transcription factors to bind. This hierarchical binding model explains how enhancers become progressively specified during development: pioneer factors establish competence, and subsequent factors refine and activate the enhancer.

The binding of transcription factors to enhancers is cooperative. Multiple factors bind to closely spaced sites, and protein-protein interactions between adjacent factors stabilize the entire complex. This cooperativity produces a sharp, switch-like response to changes in transcription factor concentration, ensuring that enhancers are either active or inactive rather than existing in intermediate states.

Role of Coactivators and Mediator

Sequence-specific transcription factors bound at enhancers do not directly contact the basal transcription machinery. Instead, they recruit coactivator complexes that bridge the enhancer-bound factors to the promoter. The Mediator complex is the central player in this process. This large, multi-subunit complex (approximately 26 subunits in humans) physically links enhancer-bound transcription factors to RNA polymerase II and the general transcription factors at the promoter.

The interaction between Mediator and the transcription machinery stimulates several steps in the Transcription Initiation process. Mediator promotes the recruitment of RNA polymerase II to the promoter, facilitates the formation of the open complex in which the DNA strands are separated, and stimulates the transition from initiation to productive elongation. Additionally, Mediator recruits the general transcription factor TFIIH, whose helicase activity is required for promoter melting.

Beyond Mediator, enhancer-bound factors recruit histone-modifying enzymes that alter chromatin structure. Histone acetyltransferases such as p300 and CBP add acetyl groups to lysine residues on histone tails, neutralizing their positive charge and weakening histone-DNA interactions. This acetylation, particularly at histone H3 lysine 27 (H3K27ac), is a hallmark of active enhancers. Conversely, histone methyltransferases and demethylases add or remove methyl groups, creating a complex histone code that influences chromatin accessibility and the recruitment of additional regulatory proteins.

Enhancer Properties and Features

Position and Orientation Independence

The defining property of enhancers is their ability to function regardless of their position or orientation relative to the target promoter. An enhancer can be placed upstream, downstream, or even within an intron of its target gene and still stimulate transcription. Similarly, flipping the enhancer to the opposite orientation does not abolish its activity.

This position and orientation independence distinguishes enhancers from promoters, which have a fixed directional relationship with the transcription start site. The mechanistic basis for this property lies in the fact that enhancers function as protein-binding platforms rather than as templates for transcription. The transcription factors bound to the enhancer present activation domains that can interact with coactivators regardless of the enhancer's orientation, and the DNA looping mechanism that brings enhancer and promoter together does not require a specific linear arrangement.

It is important to note, however, that position independence has limits. Enhancers typically act within the boundaries of their TAD, and elements located beyond these boundaries generally do not influence the promoter. Additionally, some enhancers show position-dependent effects in reporter assays, likely reflecting the influence of local chromatin context on factor binding.

Tissue-Specific Activity

Most enhancers exhibit cell-type-specific activity. A given enhancer may strongly activate transcription in one tissue while having no effect in another. This specificity arises from the requirement for specific combinations of transcription factors to be present simultaneously in the nucleus.

The immunoglobulin heavy-chain enhancer provides a classic example. This enhancer contains binding sites for multiple transcription factors, including E-box-binding proteins and factors of the ETS family. In B lymphocytes, where these factors are expressed, the enhancer is active and drives high-level immunoglobulin gene transcription. In non-lymphoid cells, the necessary factor combinations are absent, and the enhancer is silent.

Tissue specificity is not absolute but rather quantitative. Many enhancers show graded activity across different cell types, reflecting the relative abundance of activating and repressing factors. Additionally, some enhancers are active in multiple tissues but control different genes in each, depending on the three-dimensional chromatin architecture of the particular cell type.

Conservation Across Species

Enhancer sequences are often conserved across evolution, although the degree of conservation varies considerably. Some enhancers show strong sequence conservation across mammals, while others are conserved only among closely related species. The conservation pattern reflects the functional importance of the enhancer and the selective pressure to maintain transcription factor binding sites.

Comparative genomics approaches have exploited this conservation to identify putative enhancers. The VISTA enhancer browser, for example, contains thousands of human sequences with conserved noncoding regions that have been tested for enhancer activity in transgenic mice. Approximately one-third of these sequences show reproducible enhancer activity, typically in specific tissues such as the developing limb, brain, or heart.

It is important to recognize that sequence conservation is not a perfect predictor of enhancer function. Many functional enhancers show little sequence conservation, particularly in rapidly evolving lineages. Conversely, some conserved noncoding sequences lack enhancer activity in vivo. The relationship between sequence conservation and function is therefore probabilistic rather than deterministic.

Examples of Enhancers in Transcription

Beta-Globin Locus Control Region

The beta-globin locus control region (LCR) is among the most extensively studied enhancer systems. Located upstream of the beta-globin gene cluster on chromosome 11, the LCR consists of five DNase I-hypersensitive sites (HS1–HS5) that collectively control the expression of the five beta-like globin genes during development.

The LCR functions as a powerful enhancer that drives high-level, erythroid-specific expression of the globin genes. Individual hypersensitive sites contribute differentially to this activity: HS2 contains a strong enhancer that activates transcription, while HS3 and HS4 are required for chromatin opening and long-range interactions. The LCR physically loops to the active globin gene promoter, and the choice of which globin gene is activated depends on the developmental stage—the embryonic epsilon gene, the fetal gamma genes, or the adult beta gene.

Deletion of the LCR in humans causes beta-thalassemia, a disorder characterized by reduced or absent beta-globin production. This clinical phenotype demonstrates the essential role of enhancers in achieving physiologically adequate levels of gene expression. The beta-globin LCR also illustrates the principle that enhancers can regulate multiple genes within a cluster, coordinating their expression in a developmental stage-specific manner.

Enhancers in Immune Cell Development

The immune system relies heavily on enhancer-mediated gene regulation to generate the diverse cell types and activation states required for host defense. The differentiation of naive T cells into distinct effector subsets—Th1, Th2, Th17, and regulatory T cells—is controlled by lineage-specific enhancers that respond to extracellular signals.

The Th2 cytokine locus provides a well-characterized example. This locus contains the genes encoding interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13), which are coordinately regulated by a series of enhancers, including the conserved noncoding sequences CNS1 and CNS2. These enhancers are bound by the transcription factors GATA3 and STAT6, which are activated downstream of T cell receptor and cytokine receptor signaling. The enhancers loop to the cytokine gene promoters, driving high-level expression of these cytokines in Th2 cells but not in other T cell subsets.

The inducible nature of immune enhancers is particularly notable. Many enhancers in immune cells are poised—marked by histone modifications that indicate potential activity—but become fully active only after cellular activation. This poising allows rapid transcriptional responses to pathogens, as the enhancers are already primed for factor binding and require only the activation of signal-dependent transcription factors.

Enhancers in Cancer

Cancer genomes are frequently characterized by aberrant enhancer activity that drives the overexpression of oncogenes. This can occur through several mechanisms, including the amplification of enhancer regions, the mutation of enhancer sequences that creates new transcription factor binding sites, and the rearrangement of chromosomes that brings enhancers into proximity with oncogenes.

The MYC oncogene provides a paradigm for enhancer dysregulation in cancer. The MYC locus contains multiple enhancers, including the MYC enhancer cluster, which is amplified in some cancers and mutated in others. Single nucleotide polymorphisms within these enhancers can create or destroy transcription factor binding sites, altering MYC expression levels and contributing to cancer susceptibility.

A particularly striking phenomenon is "enhancer hijacking," in which chromosomal rearrangements place a strong enhancer near an oncogene that is not normally under its control. In medulloblastoma, for example, structural variants can reposition the enhancer of the growth factor receptor gene GFI1 to the vicinity of the oncogene GFI1B, driving its aberrant overexpression. Similar mechanisms have been described in multiple cancer types, including leukemia, sarcoma, and colorectal cancer.

Methods to Study Enhancers

Reporter Assays

Reporter assays provide a direct functional test of enhancer activity. In a typical assay, the candidate enhancer sequence is cloned upstream of a minimal promoter driving a reporter gene such as luciferase, green fluorescent protein (GFP), or beta-galactosidase. The construct is then introduced into cells, and reporter activity is measured.

Enhancer activity is quantified by comparing reporter expression from constructs containing the candidate enhancer to that from constructs containing only the minimal promoter. A significant increase in reporter expression indicates enhancer activity. The position and orientation independence of enhancers can be tested by cloning the candidate sequence in both orientations and at various distances from the promoter.

Reporter assays can be performed in cultured cells using transient transfection or in transgenic animals for in vivo analysis. Each approach has limitations: cell-based assays may not recapitulate the chromatin environment of the endogenous locus, while transgenic assays are more physiologically relevant but are lower throughput and more expensive.

Chromatin Immunoprecipitation (ChIP)

Chromatin immunoprecipitation identifies genomic regions bound by specific proteins, including transcription factors and histone modifications associated with enhancers. The procedure involves crosslinking proteins to DNA using formaldehyde, shearing the chromatin into fragments of approximately 200–600 base pairs by sonication, and immunoprecipitating the protein of interest with a specific antibody.

The DNA fragments associated with the immunoprecipitated protein are then identified by quantitative PCR (for candidate regions) or by high-throughput sequencing (ChIP-seq, for genome-wide analysis). Enhancers are typically marked by specific histone modifications, including H3K4me1 (monomethylation of histone H3 at lysine 4) and H3K27ac (acetylation of histone H3 at lysine 27). The presence of these marks, together with the binding of the coactivator p300, is commonly used to identify active enhancers.

ChIP experiments require careful optimization. The quality of the antibody is critical, as non-specific antibodies produce high background. Crosslinking conditions must be optimized for each protein: excessive crosslinking can mask epitopes, while insufficient crosslinking leads to loss of protein-DNA interactions. Typical formaldehyde concentrations range from 0.5% to 1%, with crosslinking times of 5–15 minutes at room temperature.

ATAC-seq and DNase-seq

Active enhancers are characterized by accessible chromatin, where nucleosomes are depleted or repositioned to allow transcription factor binding. This accessibility can be detected genome-wide using DNase-seq or ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing).

DNase-seq involves digesting chromatin with DNase I, which preferentially cleaves accessible DNA. The resulting fragments are sequenced to identify regions of open chromatin. ATAC-seq uses a hyperactive transposase (Tn5) that simultaneously fragments and tags accessible DNA with sequencing adapters. ATAC-seq requires substantially fewer cells than DNase-seq—as few as 500 cells can generate a usable dataset—making it particularly valuable for analyzing rare cell populations.

Both methods identify open chromatin regions, but not all open regions are enhancers. Promoters, insulators, and other regulatory elements are also accessible. Integration with other data types, such as histone modification profiles and transcription factor binding data, is necessary to classify accessible regions as enhancers.

3C/Hi-C Techniques

Chromosome conformation capture techniques measure the physical proximity between genomic regions in three-dimensional space. The original 3C (Chromosome Conformation Capture) method detects interactions between two known loci. Cells are crosslinked with formaldehyde, chromatin is digested with a restriction enzyme, and the resulting fragments are ligated under conditions that favor intramolecular ligation. The ligation products are then quantified by PCR to determine the frequency of interaction between the two loci.

Hi-C extends this approach to genome-wide analysis. After ligation, the DNA is sheared, and the ligation junctions are purified and sequenced. The resulting data provide a genome-wide map of chromatin interactions, from which TADs and enhancer-promoter contacts can be identified. Hi-C requires substantial sequencing depth—hundreds of millions of reads for high-resolution maps—and sophisticated computational analysis to normalize the data and identify significant interactions.

Capture-C and promoter capture Hi-C are variations that enrich for interactions involving specific regions of interest. These methods use biotinylated oligonucleotide probes to capture DNA fragments containing promoters or other regions of interest before sequencing, allowing higher resolution analysis of enhancer-promoter interactions at reduced sequencing cost.

Enhancer-Promoter Interactions

Chromatin Looping

The physical interaction between enhancers and promoters is mediated by chromatin looping, which brings these elements into close proximity despite their linear separation. This looping is dynamic and regulated, with the frequency and stability of enhancer-promoter contacts correlating with transcriptional activity.

The formation of enhancer-promoter loops requires the coordinated action of multiple protein complexes. Cohesin, a ring-shaped complex, is loaded onto chromatin by the NIPBL-MAU2 complex and extrudes DNA loops until it encounters CTCF-bound boundaries. The resulting loops bring enhancers and promoters within the same TAD into proximity, increasing the probability of functional interactions.

The stability of enhancer-promoter loops varies considerably. Some interactions are relatively stable, persisting for minutes to hours, while others are highly dynamic, forming and dissolving on timescales of seconds. Single-molecule imaging studies have revealed that enhancers and promoters undergo repeated cycles of contact and separation, with active transcription associated with more frequent and longer-lived interactions.

Phase Separation and Transcription Factories

Recent evidence indicates that enhancer-promoter communication may also involve liquid-liquid phase separation, a process in which proteins and nucleic acids form membraneless compartments within the nucleus. Transcription factors and coactivators containing intrinsically disordered regions can undergo phase separation, concentrating into droplets that contain high local concentrations of the transcription machinery.

The Mediator complex and the C-terminal domain of RNA polymerase II are particularly enriched in disordered regions that promote phase separation. These properties suggest that active enhancers may nucleate the formation of transcriptional condensates—phase-separated compartments that concentrate RNA polymerase II and associated factors at sites of active transcription.

The concept of transcription factories extends this idea. According to this model, RNA polymerase II and associated factors are concentrated in discrete nuclear foci, and multiple active genes, together with their enhancers, are recruited to these factories for transcription. This organization would allow efficient sharing of the transcription machinery among coordinately regulated genes and could explain the clustering of active genes observed in the nucleus.

Enhancer Dysregulation in Disease

Enhancer Mutations and Genetic Disorders

Mutations in enhancer sequences can cause human disease by reducing or abolishing enhancer activity. Unlike mutations in protein-coding sequences, which often produce obvious changes in protein structure, enhancer mutations typically have more subtle effects, reducing gene expression levels rather than eliminating them entirely. This quantitative nature explains why enhancer mutations often cause milder phenotypes than null mutations in the same gene.

The SHH gene and its enhancer ZRS (zone of polarizing activity regulatory sequence) illustrate this principle. The ZRS enhancer, located approximately 1 megabase upstream of the SHH coding region, controls SHH expression in the developing limb bud. Point mutations in the ZRS cause preaxial polydactyly, a condition characterized by extra digits, while deletion of the entire enhancer causes more severe limb malformations. The position of the mutation within the ZRS determines the severity of the phenotype, reflecting the disruption of specific transcription factor binding sites.

Enhancer mutations have been implicated in a wide range of developmental disorders, including holoprosencephaly, cleft palate, and congenital heart defects. The identification of these mutations has been accelerated by whole-genome sequencing, which can detect noncoding variants that are missed by exome sequencing.

Enhancer Hijacking in Cancer

Enhancer hijacking refers to the repositioning of enhancers to new genomic locations, where they activate genes that are not normally under their control. This can occur through chromosomal translocations, inversions, or other structural rearrangements that place an enhancer near an oncogene.

T cell acute lymphoblastic leukemia (T-ALL) provides well-characterized examples. In a subset of T-ALL cases, the TAL1 oncogene is activated by a translocation that brings it under the control of the T cell receptor enhancer. This enhancer is normally active in T cells, where it drives high-level expression of the T cell receptor genes. The translocation inappropriately activates TAL1, promoting leukemic transformation.

More recent studies have identified enhancer hijacking events that do not involve chromosomal rearrangements. Focal amplifications of enhancer regions can increase the copy number of enhancers driving oncogene expression, and the insertion of transposable elements can introduce new enhancer activity near proto-oncogenes. The systematic identification of these events is an active area of cancer genomics research, with implications for both diagnosis and therapy.

Common Pitfalls and Misconceptions

Enhancers vs. Promoters

A common confusion is the distinction between enhancers and promoters. Both are regulatory DNA elements that control transcription, and both bind transcription factors and recruit coactivators. However, they differ in several fundamental respects.

Promoters are located immediately upstream of the transcription start site and define where transcription begins. They contain the core promoter elements—such as the TATA Box Transcription motif, the initiator element, and the downstream promoter element—that direct the assembly of the preinitiation complex. Promoters have a fixed orientation and position relative to the transcription start site.

Enhancers, by contrast, can be located anywhere relative to their target promoter and function in either orientation. They do not themselves direct transcription initiation but rather stimulate the promoter's activity. The distinction is not always absolute: some elements can function as both promoters and enhancers, depending on context. These bidirectional elements are particularly common in the genomes of higher eukaryotes.

For a more detailed comparison, see the Difference Between Enhancer and Promoter.

Enhancers Can Act Over Long Distances

Students often assume that regulatory elements must be near their target genes. While this is true for promoters, enhancers can act over remarkable distances. The ZRS enhancer of SHH is located approximately 1 megabase from its target promoter, and enhancers in the beta-globin locus are located tens of kilobases from the genes they regulate.

The ability of enhancers to act over long distances is enabled by chromatin looping, which brings distant elements into physical proximity. The three-dimensional organization of the genome into TADs constrains these interactions, ensuring that enhancers act on appropriate target genes rather than on all genes in the vicinity.

The practical consequence of long-range enhancer action is that identifying the target gene of a given enhancer is not trivial. The nearest gene is not always the correct target, and enhancers can skip over intervening genes to regulate more distant promoters. This "skipping" behavior reflects the specificity of enhancer-promoter interactions, which are determined by the compatibility of the transcription factors bound at each element.

Enhancer Activity Is Context-Dependent

Enhancer activity is not an intrinsic property of the DNA sequence but rather depends on the cellular context. An enhancer that is strongly active in one cell type may be completely inactive in another, and its activity can change dynamically in response to developmental or environmental signals.

This context dependence has several sources. The presence or absence of specific transcription factors is the primary determinant: an enhancer is active only when the factors that bind its sequence are present in the nucleus. Chromatin state also matters: an enhancer in heterochromatin may be inaccessible to transcription factors, while the same sequence in euchromatin is available for binding.

The context dependence of enhancer activity has important implications for experimental interpretation. An enhancer identified by chromatin accessibility or histone modifications in one cell type may not be active in another. Reporter assays performed in heterologous cells may fail to detect enhancer activity that would be observed in the appropriate cellular context.

Summary and Key Takeaways

Enhancers are fundamental regulators of eukaryotic transcription, providing the specificity and flexibility required for complex gene expression programs. They function by binding sequence-specific transcription factors, recruiting coactivators, and communicating with promoters through chromatin looping. The study of enhancers has revealed principles of gene regulation that are essential for understanding development, physiology, and disease.

Frequently Asked Questions

What is an enhancer in transcription?

An enhancer is a cis-acting DNA regulatory element that increases the rate of transcription from a target promoter. Enhancers are typically 100–1000 base pairs long, contain binding sites for multiple transcription factors, and can act over long distances through chromatin looping. They are distinguished from promoters by their position and orientation independence and by their role in modulating rather than initiating transcription.

How do enhancers function in transcription?

Enhancers function by serving as platforms for the assembly of transcription factor complexes. Sequence-specific transcription factors bind to the enhancer and recruit coactivator proteins, including the Mediator complex and histone-modifying enzymes. The enhancer is brought into physical proximity with the promoter through chromatin looping, allowing the coactivators to stimulate the assembly and activity of the transcription machinery at the promoter. This stimulation increases the frequency of Transcription Initiation and promotes productive elongation.

What are examples of enhancers in transcription?

Well-studied examples include the beta-globin locus control region, which regulates globin gene expression during development; the ZRS enhancer of SHH, which controls limb development; and the immunoglobulin heavy-chain enhancer, which drives B cell-specific gene expression. Enhancers also play critical roles in immune cell differentiation, where inducible enhancers respond to extracellular signals to activate cytokine gene expression.

Can enhancers work in any orientation?

Yes, enhancers function regardless of their orientation relative to the target promoter. This orientation independence is a defining property of enhancers and reflects their mechanism of action: they serve as protein-binding platforms rather than as directional templates for transcription. The transcription factors bound to the enhancer can interact with coactivators and the promoter regardless of the enhancer's orientation in the DNA.

How are enhancers identified experimentally?

Enhancers are identified using a combination of approaches. Reporter assays test the functional activity of candidate sequences. Chromatin immunoprecipitation (ChIP) identifies regions bound by transcription factors and marked by enhancer-associated histone modifications such as H3K4me1 and H3K27ac. ATAC-seq and DNase-seq identify regions of accessible chromatin. Chromosome conformation capture techniques (3C, Hi-C) identify physical interactions between enhancers and promoters.

What is the difference between an enhancer and a promoter?

A promoter is located immediately upstream of the transcription start site and directs the initiation of transcription. It has a fixed position and orientation and contains core promoter elements such as the TATA box. An enhancer is a regulatory element that stimulates transcription from a promoter but can be located at variable distances and in either orientation. Enhancers do not themselves direct transcription initiation but rather modulate the activity of promoters.

Do enhancers always act on the nearest gene?

No, enhancers do not always act on the nearest gene. Enhancer-promoter interactions are determined by the compatibility of transcription factors bound at each element and by the three-dimensional organization of the genome. Enhancers can skip over intervening genes to regulate more distant promoters, and the boundaries of topologically associating domains constrain which promoters an enhancer can access.

Key Takeaways

Enhancers are cis-acting DNA elements that increase transcription from target promoters, functioning independently of position and orientation.
Enhancers work through the binding of sequence-specific transcription factors, recruitment of coactivators such as Mediator, and physical communication with promoters via chromatin looping.
Enhancer activity is highly context-dependent, determined by the combination of transcription factors present in a given cell type and by the chromatin state.
Enhancers can act over distances of up to a megabase or more, and their target specificity is constrained by topologically associating domains.
Enhancer dysregulation, including mutations and enhancer hijacking, contributes to developmental disorders and cancer.
Enhancers are identified experimentally using reporter assays, ChIP-seq, ATAC-seq, and chromosome conformation capture techniques.
Understanding enhancer function is essential for interpreting gene regulatory mechanisms in development, physiology, and disease.